Patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should discuss risks with specialists
With the rise of GLP-1s, before-and-after pictures of people on their weight-loss journeys have flooded social feeds
By supporting a more structured regulatory pathway, the FDA has the opportunity to enhance patient safety, quality standards, and oversight while encouraging continued scientific and clinical evaluation of peptides such as BPC-157 & KPV.
There is no best GLP-1 patch, because no GLP-1 patch delivers a therapeutic dose of anything
10.1074/jbc.275.15.10761 47 RaibleD
Thyroid dysfunction, low testosterone, perimenopause, and elevated cortisol all directly undermine weight loss results and patients who succeed on GLP-1 therapy without addressing these underlying imbalances frequently regain weight when tapering off